Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.21
-0.14
(-5.96%)
USD |
NASDAQ |
Nov 13, 10:26
Bridgebio Oncology Therapeutics Free Cash Flow (Quarterly) : -28.38M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -28.38M |
| June 30, 2026 | -44.41M |
| March 31, 2026 | -35.94M |
| December 31, 2025 | -42.31M |
| September 30, 2025 | -71.16M |
| June 30, 2025 | -23.52M |
| Date | Value |
|---|---|
| March 31, 2025 | -19.76M |
| December 31, 2024 | -15.04M |
| September 30, 2024 | -39.38M |
| June 30, 2024 | -0.0291M |
| March 31, 2024 | -0.618M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -47.06M |
| IRulya Therapeutics, Inc. | -18.89M |
| PepGen Inc. | -13.18M |
| Q32 Bio, Inc. | -4.47M |
| Arrowhead Pharmaceuticals, Inc. | -181.32M |